The EMET team brings together doctors, pharmacists and research professors specializing in the evaluation and use of drug and non-drug therapies, around a single project built on two axes:
- the evaluation of therapies in clinical trials or observational studies;
- the construction of explanatory and predictive models, to better understand and therefore predict the effect of therapies, simulate their impacts at the individual and population level, and improve the innovation paradigm.
The EMET team is therefore part of two major dynamics in therapy: analysis of the level of evidence and precision medicine.
The fields of application are cardiovascular and metabolic diseases, primary care medicine, rare pediatric diseases (including genetic and autoimmune diseases), oncology and infectious diseases.
EMET members implement approaches using different mathematical models: direct comparison and network meta-analysis, pharmacokinetic/pharmacodynamic analysis, Bayesian networks and machine learning.
The EMET team is specially involved in the teaching of pharmacology and therapeutics and the modeling of the treatment effect through the coordination of the Masters 2 Clinical Evaluation (EC) and Pharmacology modeling and clinical trials (PHAME), Interpretation of Therapeutic Trials (IET), Training of investigators in clinical drug trials (FIEC) and Training of clinical research assistants and clinical study technicians (FARCTEC). Teacher-researchers are also involved in the first (pharmacology), second (pharmacology / therapeutics, pharmacy) and third cycles (general medicine, pediatrics, internal medicine) in health training courses.
The members of the EMET team through their work and their interactions with the other components of the LBBE, National societies, governmental (HAS) or international (EMA) agencies, and the Hospices Civils de Lyon, are invested in current societal issues: rationalization of the use of health product resources, research ethics, gender equality, rationality of approaches in analyzing the diversity of human populations.
Display of 1 to 30 publications on 169 in total
Defining standard and high dosages for β-lactam agents administered by intermittent, prolonged or continuous infusion: a PK/PD simulation study
Journal of Antimicrobial Chemotherapy . 78 ( 11 ) : 2762–2769
A Knowledge-Based Approach for Evaluating Impact of Therapeutic Strategies
ICAART 2023 - 15th International Conference on Agents and Artificial Intelligence . 3 : 1036-1046
Machine-Learning Exploration of Exposure-Effect Relationships of Cisplatin in Head and Neck Cancer Patients
Pharmaceutics . 14 ( 11 ) : 2509
Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues
Clinical Pharmacokinetics . 61 ( 10 ) : 1443-1456
Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis
Pharmaceutics . 14 ( 8 ) : 1750
Seventeen Cases of Daptomycin-Induced Eosinophilic Pneumonia in a Cohort of Patients Treated for Bone and Joint Infections: Proposal for a New Algorithm
Open Forum Infectious Diseases . 9 ( 11 ) : ofac577
Predicted Impacts of Booster, Immunity Decline, Vaccination Strategies, and Non-Pharmaceutical Interventions on COVID-19 Outcomes in France
Vaccines . 10 ( 12 ) : 2033
An Investigation of O-Demethyl Tramadol/Tramadol Ratio for Cytochrome P450 2D6 Phenotyping: The CYTRAM Study
Pharmaceutics . 14 ( 10 ) : 2177
Selected and simplified FDI criteria for assessment of restorations
Journal of Dentistry . 122 : 104109
How do they add up? The interaction between the placebo and treatment effect: A systematic review
British Journal of Clinical Pharmacology .
Place of a new radiological index in predicting pulp exposure before intervention for deep carious lesions
Oral Radiology . 38 ( 1 ) : 89-98
Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference
Journal of Antimicrobial Chemotherapy . 76 ( 5 ) : 1250-1257
Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile
Antimicrobial Agents and Chemotherapy . 65 ( 9 ) : e0104321
Expected Evolution of COVID-19 Epidemic in France for Several Combinations of Vaccination Strategies and Barrier Measures
Vaccines . 9 ( 12 ) : 1462
Population Pharmacokinetics and Dosing Simulation of Vancomycin Administered by Continuous Injection in Critically Ill Patient
Antibiotics . 10 ( 10 ) : 1228
Rifampicin exposure reveals within-host Mycobacterium tuberculosis diversity in patients with delayed culture conversion
PLoS Pathogens . 17 ( 6 ) : e1009643
Inconclusive efficacy of intervention on upper-limb function after tetraplegia: A systematic review and meta-analysis
Annals of physical and rehabilitation medicine . 63 ( 3 ) : 230-240
Publication language and the estimate of treatment effects of physical therapy on balance and postural control after stroke in meta-analyses of randomised controlled trials
PLoS ONE . 15 ( 3 ) : e0229822
The contribution of genomics in the medicine of tomorrow, clinical applications and issues
Thérapie . 74 ( 1 ) : 9-15
Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients
Antimicrobial Agents and Chemotherapy . 63 ( 11 ) : e00993-19
Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review
Anaesthesia Critical Care & Pain Medicine .
The limitations of observation studies for decision making regarding drugs efficacy and safety
Alternative and Complementary Therapies . 74 ( 2 ) : 181-185
Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response? A meta-analysis
Journal of Cystic Fibrosis .
Apport de la génomique dans la médecine de demain, applications cliniques et enjeux
Thérapie . 74 ( 1 ) : 1-8
Immune system modelling in case of a septic shock
29TH EUROPEAN SYMPOSIUM ON COMPUTER AIDED PROCESS ENGINEERING, . : 1093-1098
Causes and consequences of variation in offspring body mass: meta-analyses in birds and mammals
Biol. Rev . 93 : 1 - 27
Prospective Cohort Study of the Tolerability of Prosthetic Joint Infection Empirical Antimicrobial Therapy
ANTIMICROB. AGENTS CHEMOTHER. . 62 ( 10 )
Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages
Tuberculosis . 111 : 67-70
Determinants of amikacin first peak concentration in critically ill patients
Fundamental & Clinical Pharmacology .